Table 4.
Clinical characteristics of patients of fourth group with chronic HBV infection
| Patient No. | Sex/Age | HBV DNA (IU/mL) | INR | ALT (IU/mL)/TBIL (μM) | HAI score | Fibrosis score | Experiment |
|---|---|---|---|---|---|---|---|
| 1 | f/32 | 18600000 | NA | 23/NA | 3 | 0 | A |
| 2 | m/44 | 8600000 | 1.77 | 136/120 | 15 | 2 | A |
| 3 | m/48 | 4660000 | 1.34 | 71/154 | 12 | 2 | A |
| 4 | m/28 | 53700000 | 0.91 | 258/18 | 7 | 2 | A, WB |
| 5 | m/40 | 12980 | 1.11 | 410/55.1 | 15 | 5 | A |
| 6 | m/22 | 6190 | 0.86 | 2436/97 | 12 | 2 | A |
| 7 | m/37 | 7880 | 0.8 | 56/- | 5 | 0 | A |
| 8 | m/33 | 2290 | 1.54 | 621/222.2 | 7 | 2 | A |
| 9 | m/41 | 2940 | 0.87 | 22/10.1 | 4 | 0 | A |
| 10 | m/37 | <100 | 0.98 | 398/46.6 | 13 | 2 | A |
| 11 | f/34 | 41000 | 0.97 | 41/8.8 | 8 | 3 | A, coIP |
| 12 | m/41 | 414000 | 0.85 | 2400/116 | 13 | 2 | A |
| 13 | m/24 | 29700000 | 0.99 | 44/14.2 | 7 | 2 | A |
| 14 | m/33 | 15600000 | NA | 1999/NA | 13 | 3 | IH, Confocal |
| 15 | f/45 | 34500000 | NA | 35/NA | 8 | 0 | IH, Confocal |
| 16 | m/26 | 23070000 | 1.65 | 2545/267.6 | 8 | 2 | WB, coIP |
| 17 | m/34 | <100 | NA | <40/NA | 3 | 1 | IH, Confocal |
| 18 | m/25 | 117000000 | NA | 78/NA | 8 | 2 | IH |
| 19 | m/45 | 8570 | NA | 140/NA | 4 | 0 | IH |
| 20 | f/24 | <100 | 1.0 | 22/13.1 | 6 | 6 | RS |
| 21 | f/37 | 8240 | 1.05 | 26/13.4 | 4 | 5 | RS |
| 22 | m/47 | 6050000000 | 1.76 | 2294/130 | 12 | 2 | RS |
| 23 | m/52 | 18500000 | 1.61 | 399/470 | 12 | 2 | RS |
A: caspase-1 activity assay; coIP: co-immunoprecipitation; IH: immunofluorescence histochemistry; RS: RNA sequence; NA: not available.